A Study to Evaluate Vaginal Versus Intramuscular Progesterone for Prevention of Recurrent Spontaneous Preterm Birth
Official Title: Vaginal Versus Intramuscular Progesterone for Prevention of Recurrent Spontaneous Preterm Birth (VIP)
The purpose of this study is to compare the effectiveness of vaginal progesterone vs. intramuscular progesterone for the prevention of recurrent spontaneous preterm birth.
- Pregnant women with a single fetus
- 18 years and older with an estimated gestational age less than 24 weeks and
- Have had a prior spontaneous preterm birth of a single fetus between 16 weeks and 36 weeks and 6 days
- Have not already begun progesterone therapy for preterm birth prevention (ie after 16 weeks gestation; first trimester use is not a contraindication).
Anna Bartholomew, RN